CRISPR-Cas9 technology, while revolutionary in genetic engineering, presents significant experimental challenges.  Off-target effects, resulting in unintended genomic modifications, remain a major hurdle, necessitating rigorous validation strategies such as whole-genome sequencing and sophisticated bioinformatic analyses.  Delivery systems also pose difficulties; efficient and targeted delivery of the CRISPR-Cas9 complex to specific cells or tissues, particularly in vivo, remains a substantial limitation.  Furthermore, the mosaicism frequently observed following CRISPR application, where only a subset of cells exhibit the intended modification, complicates interpretation of results and limits therapeutic efficacy.  Achieving consistent and predictable editing efficiency across diverse cell types and organisms continues to be problematic, demanding optimization of parameters such as guide RNA design and Cas9 concentration.  Finally, ethical concerns surrounding germline editing and the potential for unforeseen consequences underscore the need for cautious and responsible application of this powerful technology, demanding rigorous preclinical research and robust regulatory frameworks.  Overcoming these challenges is crucial for realizing the full therapeutic and research potential of CRISPR.